|
|
|
Volumn 127, Issue 29-30, 1997, Pages 1234-1241
|
|
Economic benefits of ACE inhibitors in the treatment of chronic heart failure in Switzerland;Wirtschaftlichkeit der ACE-Hemmung in der Therapie der chronischen Herzinsuffizienz in der Schweiz: Evaluation auf der Grundlage der SOVLD-Studie
a
a
NONE
(Switzerland)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
ENALAPRIL;
PLACEBO;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG COST;
FOLLOW UP;
HEALTH CARE COST;
HEALTH ECONOMICS;
HEART FAILURE;
HUMAN;
MAJOR CLINICAL STUDY;
MORBIDITY;
MORTALITY;
RANDOMIZED CONTROLLED TRIAL;
SOCIOECONOMICS;
SWITZERLAND;
ADULT;
AGED;
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS;
COST-BENEFIT ANALYSIS;
DOUBLE-BLIND METHOD;
ENALAPRIL;
FEMALE;
HEART FAILURE, CONGESTIVE;
HUMANS;
LENGTH OF STAY;
MALE;
MIDDLE AGED;
PATIENT ADMISSION;
PROSPECTIVE STUDIES;
SWITZERLAND;
VENTRICULAR DYSFUNCTION, LEFT;
|
|
EID: 0030739174
PISSN: 00367672
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (12)
|
|
References (34)
|
